|
|
|
! All documents are reproduced with the permission of the copyright
owner. Further reproduction or distribution is prohibited without permission. |
|
|
|
|
|
Citation
style: ProQuest Standard |
|
|
|
|
Document 1 of 1 |
|
|
|
People: |
Mercadante,
Otavio Azevedo |
|
Author(s): |
Stan
Lehman |
|
Document
types: |
News |
|
Dateline: |
SAO PAULO, Brazil |
|
Section: |
Health |
|
Publication
title: |
Kingston
Whig - Standard. Kingston, Ont.: Oct 12,
2004. pg. 23 |
|
Source
type: |
Newspaper |
|
ISSN/ISBN: |
11974397 |
|
ProQuest
document ID: |
716176691 |
|
Text
Word Count |
702 |
|
Document
URL: |
http://proquest.umi.com/pqdweb?did=716176691&Fmt=3&clientId=17280&RQT=309&VName=PQD |
|
Abstract (Document Summary) |
|
The new
painkiller could one day replace morphine, which is widely used to alleviate
the pain of cancer patients and other chronic pain sufferers, [Otavio Azevedo
Mercadante] says. He says that the potential painkiller is 600 times stronger
than morphine and that tests done with rats indicate it's not addictive. Painkilling
properties similar to the ones found in the rattlesnake's poison have not
been discovered in the venom of other snakes used by the institute to produce
antivenin, Mercadante says. Colour Photo:
The Associated Press / A lab technician extracts venom from a rattlesnake at
the Butantan Institute, in Sao Paulo, Brazil. Researchers say they are close
to developing a painkiller more powerful than morphine, based on rattlesnake
venom. |
![]()
|
Full Text (702 words) |
||
|
(Copyright The Kingston Whig-Standard 2004) Brazilian
researchers hope to turn rattlesnake poison into potent drug SAO PAULO,
Brazil - The rattlesnake, known only as No. 0148, isn't too pleased when lab
technician Eladio Soares de Almeida forces its mouth open, plunges its two
fangs into a cellophane- covered jar and squeezes out its deadly poison. The rattler's
venom, like that of the more than 5,000 other poisonous reptiles at the
Butantan Institute, is used to produce antivenin that saves the lives of
people bitten by rattlesnakes, coral snakes and South American vipers known
as the "jararaca," "surucucu" and "urutu."
Antitoxins against spider and scorpion bites are also produced at the
institute. While the
production of antivenins has been the institute's hallmark since its founding
in 1901 by scientist Vital Brazil Mineiro da Campanha, it also is one of
Latin America's leading makers of vaccines, says Otavio Azevedo Mercadante,
the institute's director. In July,
scientists at the institute announced a possible new line of work: someday
producing painkillers based on the venom of rattlesnakes. The poison of
the rattlesnake may one day lead to a painkiller more powerful than morphine
- and perhaps without the addiction, the institute says, although it stresses
that years of development and testing lie ahead. "After
more than five years of hard work our scientists isolated and chemically
synthesized the analgesic properties of the rattlesnake's poison, which will
allow us to make what could be one of the strongest painkillers ever
produced," says Mercadante, whose 1,000-employee operation is part of
the Sao Paulo State Health Department. The origins of
the approach date back nearly 100 years, when the institute's founder
observed the venom's analgesic properties while studying the effect of
diluted rattlesnake poison on humans. The new
painkiller could one day replace morphine, which is widely used to alleviate
the pain of cancer patients and other chronic pain sufferers, Mercadante
says. He says that the potential painkiller is 600 times stronger than
morphine and that tests done with rats indicate it's not addictive. The drug still
hasn't been tested on monkeys, which is a crucial step before human testing.
And even if testing goes well, the institute projects the drug wouldn't reach
the market for at least 10 years. John C. Perez,
director of Texas A&M University's Natural Toxins Research Center, notes
a number of hurdles: Is the drug addictive? Are there side effects? How long
does the painkilling effect last? Can the drug be produced inexpensively and
easily? Mercadante
says the questions can only be answered after the painkiller is tested on
humans. Others also are researching the painkilling properties of various
poisons. Perez notes
Israel's Shulov Institute for Science developed the Zep-3 painkiller from
viper poison. In January,
the Journal of the American Medical Association published a report on the
painkilling qualities of a synthetic form of a venom from the Conus Magus
cone snail, which lives in shallow tropical saltwater. It said the venom
could ease the pain in cancer and AIDS victims who get no relief from morphine
or other conventional painkillers. Painkilling
properties similar to the ones found in the rattlesnake's poison have not
been discovered in the venom of other snakes used by the institute to produce
antivenin, Mercadante says. "But we
have found anticoagulant, anti-inflammatory and antihypertensive properties
in the poison of other specimens," he says. "Research is under
way." Rattlesnake
venom itself won't be needed to produce the potential painkiller because its
analgesic-producing molecules have been synthesized, but the institute still
needs its snake for the poison used to produce antivenin. A snake's
venom is extracted once a month and injected into one of the hundreds of
horses kept by the institute at a ranch on the outskirts of Sao Paulo. Once
the horse has produced enough antibodies, five per cent of its blood is
extracted and used to make antivenin. Horses are
used in this process because they are "stronger than most animals and
their blood is ideal for the production of antivenins," Mercadante says.
|
|
|
|
Copyright © 2004
ProQuest Information and Learning Company. All rights reserved. Terms
& Conditions |
|
|
|
Please do not reply
directly to this email. Use the following link to contact ProQuest: http://www.proquest.com/division/cs-support.shtml |